EFFICACY AND SAFETY OF VWF CONCENTRATES IN A COHORT OF 93 PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE ENROLLED IN 3WINTERS-IPS: RESULTS OF THE 2-YEAR PROSPECTIVE CLINICAL OBSERVATION

被引：0
|
作者：
Peake, I. R. [1 ]
Federici, A. B. [2 ]
机构：
[1] Univ Sheffield, Dept Dent & Hlth, Fac Med, Sheffield, S Yorkshire, England
[2] Univ Milan, L Sacco Univ Hosp, Hematol & Transfus Med, Milan, Italy
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-44
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [21] French cohort of thirty-seven patients with type 3 von Willebrand disease: Molecular and clinical features
    Boisseau, P.
    Ternisien, C.
    Aouba, A.
    Volot, F.
    Trossaert, M.
    Sigaud, M.
    Dreyfus, M.
    Itzhar, N.
    Caron, C.
    Fressinaud, E.
    Goudemand, J.
    Veyradier, A.
    HAEMOPHILIA, 2012, 18 : 200 - 200
  • [22] Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a rebuttal
    Favaloro, E. J.
    Bonar, R.
    Marsden, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (07) : 1455 - 1458
  • [23] Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.
    Federici, Augusto B.
    Bucciarelli, Paolo
    Iorio, Alfonso
    Castaman, Giancarlo
    Mazzucconi, Maria Gabriella
    Morfini, Massimo
    Rocino, Angiola
    Mannucci, Pier M.
    BLOOD, 2009, 114 (22) : 1356 - 1357
  • [24] Efficacy and safety of high-intermediate-purity VWF/FVIII concentrates given repeatedly to severe patients with Von Willebrand disease: An Italian cohort study on 32 intensively treated cases.
    Federici, Augusto B.
    Cedron, Belinda J.
    Scimeca, Barbara
    Canciani, Maria T.
    Mannucci, Pier M.
    BLOOD, 2006, 108 (11) : 94B - 94B
  • [25] GOOD EFFICACY AND SAFETY OF DESMOPRESSIN USED TO MANAGE BLEEDS, DELIVERIES AND SURGERIES IN VON WILLEBRAND DISEASE: RESULTS OF THE INTERNATIONAL PROSPECTIVE STUDY IN A COHORT OF 225 PATIENTS
    Federici, A. B.
    HAEMATOLOGICA, 2015, 100 : 25 - 25
  • [26] Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a reply to a rebuttal
    Castaman, G.
    Baronciani, L.
    Canciani, M. T.
    Federici, A. B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (07) : 1458 - 1460
  • [27] Long-term prophylactic treatment of juvenile von Willebrand type 2 and 3 patients with two different von Willebrand factor concentrates a two-center cohort study
    Halimeh, S.
    Kruempel, A.
    Rott, H.
    Manner, D.
    Mesters, R.
    Nowak-Goettl, U.
    HAEMOPHILIA, 2010, 16 : 149 - 149
  • [28] Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Gossec, Laure
    Mcinnes, Iain B.
    Ritchlin, Christopher T.
    Landewe, Robert B. M.
    Asahina, Akihiko
    Ink, Barbara
    Heinrichs, Andrea
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1363 - 1382
  • [29] Molecular characteristics and recombinant protein expression of type 2 and type 3 von Willebrand disease: studies of a Chinese cohort of 25 patients
    Yin, J.
    Su, J.
    Ma, Z.
    Zhao, X.
    Wang, Z.
    Yu, Z.
    Ouyang, W.
    Bai, X.
    Ruan, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 : 92 - 93
  • [30] Prevalence, clinical-molecular diagnosis and management of patients with von Willebrand disease type 3 (PCMDM-VWD3): an international prospective study
    Federici, A. B.
    HAEMOPHILIA, 2010, 16 (02) : 389 - 389
12345